导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.76% | 1261/4773 |
| 近一周 | -2.27% | 2714/5458 |
| 近一月 | -4.87% | 3128/5421 |
| 近一季 | -3.94% | 2171/5205 |
| 近半年 | -3.81% | 2502/4920 |
| 近一年 | 11.04% | 959/4361 |
| 近两年 | 73.55% | 921/2954 |
| 近三年 | 37.54% | 801/2253 |
| 成立以来 | 69.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.00% 1103/4961 |
20.43% 1228/5312 |
- - |
- - |
| 2025 | 34.97% 1012/4813 |
3.58% 1067/3635 |
2.97% 1229/4076 |
23.39% 1545/4524 |
2.55% 913/4813 |
| 2024 | 2.85% 1953/3463 |
-2.04% 1311/2808 |
-3.71% 1411/3014 |
10.04% 2653/3129 |
-0.91% 1542/3463 |
| 2023 | -9.05% 1093/2656 |
6.17% 716/2280 |
-5.46% 1464/2385 |
-4.30% 1108/2515 |
-5.32% 1321/2655 |
| 2022 | -16.06% 447/2207 |
-10.09% 377/1919 |
5.42% 906/2016 |
-10.78% 450/2113 |
-0.73% 1643/2208 |
| 2021 | 16.66% 263/1822 |
3.21% 193/1255 |
7.87% 663/1330 |
4.58% 335/1466 |
0.20% 1160/1822 |
| 2020 | - - |
- - |
18.72% 327/1067 |
8.99% 686/1164 |
2.04% 1012/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 嘉实中证500指数增强C VS. 长安沪深300非周期A(740101) |